about
Adult T-cell leukemia cells over-express the multidrug-resistance-protein (MRP) and lung-resistance-protein (LRP) genesBreast cancer resistance protein directly confers SN-38 resistance of lung cancer cells.Phase II study of irinotecan combined with carboplatin in previously untreated non-small-cell lung cancer.A phase I trial of carboplatin and etoposide for elderly (>or=75 year-old) patients with small-cell lung cancer.A phase I study of amrubicin and carboplatin for previously untreated patients with extensive-disease small cell lung cancer.Pulmonary Artery Sarcoma Overexpressing Platelet-derived Growth Factor Receptor α.Effects of renal function on pharmacokinetics of recombinant human granulocyte colony-stimulating factor in lung cancer patients.Prognostic significance of clinical factors and Akt activation in patients with bronchioloalveolar carcinomaTubular adenocarcinoma of the thymus: case report and review of the literature.A human breast cancer model for the study of telomerase inhibitors based on a new biotinylated-primer extension assay.Interactions of ofloxacin and erythromycin with the multidrug resistance protein (MRP) in MRP-overexpressing human leukemia cells.Interstitial pneumonia probably associated with sorafenib treatment: An alert of an adverse event.A fatal case of acute myocardial infarction following the improvement of influenza A(H1N1)pdm2009-related acute myocarditis.[Two cases of acute respiratory distress syndrome related to zinc fumes and zinc dust inhalation].BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer.Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells.Pulmonary mucormycosis (Cunninghamella bertholletiae) with cavitation diagnosed using ultra-thin fibre-optic bronchoscopy.Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.Novel camptothecin analogues that circumvent ABCG2-associated drug resistance in human tumor cells.Expression of interleukin 6 and its receptor in human gastric and colorectal cancers.Radiologically occult lung cancer in the peripheral region.Multiple gammac-receptor expression in adult T-cell leukemia.Dimethyl sulfoxide (DMSO) causes a reversible inhibition of telomerase activity in a Burkitt lymphoma cell line.Alert Regarding Cisplatin-induced Severe Adverse Events in Cancer Patients with Xeroderma Pigmentosum.Bronchial artery aneurysm as a cause of atelectasis.Effects of androgens on telomerase activity in normal and malignant prostate cells in vitro.Phase I study of pemetrexed and concurrent radiotherapy for previously untreated elderly patients with locally advanced non-squamous non-small cell lung cancer.Micronutrient status and glutathione peroxidase in bedridden patients on tube feeding.Histone deacetylase inhibitors suppress telomerase reverse transcriptase mRNA expression in prostate cancer cells.Polymorphism of CYP2C19 and gastric emptying in patients with proton pump inhibitor-resistant gastric ulcers.Phase I study of irinotecan and cisplatin with concurrent split-course radiotherapy in limited-disease small-cell lung cancer.Antiproliferative effects of the histone deacetylase inhibitor FR901228 on small-cell lung cancer lines and drug-resistant sublines.High-risk populations for nasal carriage of methicillin-resistant Staphylococcus aureus.Gefitinib increases serum concentrations of oral irinotecan and SN-38 without increasing the biliary concentration of SN-38 in rats.Chronic necrotizing pulmonary aspergillosis following cryptococcal infection of the lung.Nivolumab infusion reaction manifesting as plantar erythema and pulmonary infiltrate in a lung cancer patient.Pulmonary pleomorphic carcinoma with few PD-1-positive immune cells and regulatory T cells that showed a complete response to nivolumab.Remarkable response of nivolumab-refractory lung cancer to salvage chemotherapy.Pitfalls in diagnosis with the use of circulating tumor-derived epidermal growth factor receptor mutations in lung cancer harboring pretreatment T790M.Autoimmunity to heat shock protein 40 in ulcerative colitis.
P50
Q28139494-395D8265-34A3-4342-8495-8CAB178C362EQ31856730-82C3BA20-780B-4706-A8D7-0B66FFF7BBEDQ33362579-898D2924-5C11-4184-93F8-0D8E16FF8E71Q33370216-AD06C5DE-5298-45A8-92BE-F45923567DB0Q33384277-5960A080-0726-483C-9F89-DF6312F3277BQ33760771-E161F10E-04D9-40AB-BC3C-1EA8A5EF8665Q33982472-7FDBA4CB-5D09-4666-8CE3-C8D60144576BQ35741627-C610B806-EF0E-40DB-8FA1-763D2AC9255CQ36588656-39C9CEF3-8E70-45DE-8F58-05C2736E566CQ36620351-AF643EF5-8547-4B4B-B6CA-0AAA84D282F4Q39474195-A8219523-2246-42E7-8B10-2FCC21A2DD87Q39931322-50BEF6AD-87C1-43D8-8B3F-D73968DCAB08Q40190907-A5ADD433-9F29-454C-B9F3-1C63A87A3429Q40203608-1434F29B-252F-4108-87CF-A2E1F3AC5D83Q40307963-6CA652C6-0ACF-439E-B2C5-38B0E2EF506FQ40410062-D6388180-41B5-461A-8A69-8BE877F8465CQ40424633-18CF4487-FE0F-436A-9093-CC3B969F394FQ40453744-7275652D-54D1-409C-BFD3-7C7891C99598Q40550555-CBFCD7E5-E4DF-454F-A8CC-C29291A0D34EQ40646004-2C34E89C-0B17-45E1-9CDF-EAF1FE00DA52Q40665533-BFA89748-3DF2-4A4E-A4B8-8C934DC9FDB0Q40704768-45FD8F4F-9C80-46BC-830F-D749AF9C39ADQ41022028-56043F32-C42C-463F-A034-D215C57D2005Q42211629-424308B7-5A69-47B4-8B6B-D1405A894EC4Q42451181-F80155FE-2286-4774-B26C-817D4BCB5D91Q42487576-C5410262-A72E-4CA9-9966-89833AFA6149Q43055501-AF462EB0-83AD-466E-B50D-FD446E155AD7Q43686887-C396A549-D3A0-4FB2-BC27-642598FDBBD3Q43864439-99A9E6B4-67A6-4F3A-87FD-53CE39176EF7Q44139577-86D4AA02-C749-4025-B92E-0CC1BF45C9B1Q44176815-9C24A356-D65C-4F9B-8F32-ABFDB8E21C39Q44304210-13C236C6-EE51-49C6-9A80-5EB28D238093Q45004651-3FDD5069-955A-4D71-A656-119C17FA07A4Q46333762-19DD876D-0FAB-42AD-84C2-94B2A6CBF370Q46624451-13750A9C-C79A-4669-AEA6-D30F2029F2F8Q47114820-DC7202DF-2AD3-4506-A2C8-E4591E9E8131Q47713714-5A208123-6EDC-4545-A97B-98F2AAD9B348Q47734616-052DF24E-058E-4103-8D0F-203B090DEDFAQ47734628-2614C1AF-97A4-490C-869D-B27C2F46B8EBQ47778398-60DD2AF2-E517-4CDF-BFE8-D320A012A786
P50
description
researcher
@en
name
H Soda
@en
H Soda
@nl
type
label
H Soda
@en
H Soda
@nl
prefLabel
H Soda
@en
H Soda
@nl
P106
P31
P496
0000-0003-4993-1837